Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706)

Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706)

Abstract Hematological patients at higher risk of severe COVID‐19 were excluded from the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccine trials. In this single‐center observational prospective study (NCT05074706), we evaluate immune response in the hematological patients followe...

Full description

Bibliographic Details
Main Authors: Elisa Bossi, Andrea Aroldi, Lorenza Maria Borin, Luisa Verga, Diletta Fontana, Federica Cocito, Beatrice Manghisi, Giovanni Rindone, Fabrizio Cavalca, Alessia Ripamonti, Monica Raggi, Sergio Maria Ivano Malandrin, Annalisa Cavallero, Laura Antolini, Diego Bonardi, Rocco Giovanni Piazza, Carlo Gambacorti‐Passerini
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:eJHaem
Subjects:
cellular immune response
COVID‐19
hematological disorders
mRNA vaccine
seroconversion
Online Access:https://doi.org/10.1002/jha2.544

Internet

https://doi.org/10.1002/jha2.544

Similar Items